Medical Condition News

RSS

Health Canada approves Microsulis Medical's Accu2i percutaneous microwave tissue ablation system

Microsulis Medical Limited, the leading company in microwave technology for medical devices, today announced that it has received approval from Health Canada for the Acculis Accu2i percutaneous microwave tissue ablation system for the coagulation of soft tissue during surgical procedures.

1 Feb 2011

Research sheds new light on venous thromboembolism following liver resections

Patients undergoing liver surgery have long been considered to be at low risk of venous thromboembolism. However, pulmonary embolism has recently emerged as an increasingly frequent and potentially fatal complication following liver resections.

1 Feb 2011

Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

BELLUS Health announced today the results of the phase I clinical study for NRM8499, a prodrug of tramiprosate, intended for the treatment of Alzheimer's disease.

1 Feb 2011

Mayo Clinic opens new center to deliver optimal health care solutions

Mayo Clinic announced the launch of a new initiative focused on creating new and improved approaches to delivering health care. The Center for the Science of Health Care Delivery will design, implement, measure and disseminate high-value health care best practices with initial focus areas that include wellness and the prediction, prevention, and management of chronic diseases.

1 Feb 2011

$FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma$

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma.

1 Feb 2011

Eurogentec, ImaginAb announce collaboration to produce engineered antibody fragments

ImaginAb, and Eurogentec S.A. announce a development collaboration to establish a novel system for producing engineered antibody fragments. The two companies will produce ImaginAb's optimized antibody fragments with Eurogentec's high-performance Pichia pastoris expression system.

1 Feb 2011

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).

1 Feb 2011

Scientist identifies natural signaling molecule that can prevent Hemophilia A

A scientist from The Scripps Research Institute has identified a new role for a natural signaling molecule in preventing blood clot formation. The molecule could become a target for the development of novel and cost-effective treatments for blood clotting diseases such as Hemophilia A.

1 Feb 2011

New research finding shows strong relationship between gut bacteria and fatty liver

The more we learn about biology, the closer we get to being able to treat disease - and the more complicated our understanding of disease itself becomes. A new research finding showing a strong relationship between complex microbial ecologies in human intestines and the common but serious medical condition known as fatty liver illustrates this paradox.

1 Feb 2011

Abbott receives US regulatory clearance and Japanese approval for TREK Coronary Dilatation Catheters

Abbott today announced it has received regulatory clearance in the United States and approval in Japan for its TREK and MINI-TREK Coronary Dilatation Catheters for the treatment of coronary artery disease. The TREK system is used in angioplasty procedures and is designed to enable interventional cardiologists to open patients' narrowed coronary arteries. The TREK system received CE Mark and was launched in Europe in May 2010.

1 Feb 2011

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

Boston Scientific Corporation today announced that the U.S. Food and Drug Administration has approved its Renegade HI-FLO Fathom Pre-Loaded System for selective access and delivery of diagnostic, embolic and therapeutic materials into the peripheral vasculature.

1 Feb 2011

MRI T2 can determine iron overload in beta-thalassemic patients

Iron overload is a common and serious problem in thalassemic major patients. As iron accumulation is toxic in the body's tissues, accurate estimation of iron stores is of great importance in these patients to prevent iron overload by an appropriate iron chelating therapy.

1 Feb 2011

Researchers study peripheral blood Tregs as disease marker of gastric cancer

T-regulatory lymphocytes are a subset of T lymphocytes that are involved in the mechanism of immunotolerance to self- and allo-antigens. Activity of these cells is one of the mechanisms of immune evasion of tumors, which inhibits the antitumor activity of effector cells.

1 Feb 2011

FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator

Mederi Therapeutics Inc. announced today that it has received FDA 510(k) clearance for its new MDRF1 Generator.

1 Feb 2011

Cappella initiates multi-center Italian Sideguard open label clinical study

Cappella Medical Devices announces initiation of the multi-center Italian Sideguard® open label clinical study. The Principal Investigator (PI) of the study, Dr. Giuseppe Massimo Sangiorgi at the Policlinico di Modena - University of Modena and Reggio Emilia, in Modena, Italy stated, "The side branch ostium anatomy requires a unique technology solution to effectively manage and optimize treatment.

1 Feb 2011

Histamine can be an important molecule to develop new treatments for MS

If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.

1 Feb 2011

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.

31 Jan 2011

Researchers to develop computer-assisted diagnosis tools for pathologists

Researchers are leveraging Ohio Supercomputer Center resources to develop computer-assisted diagnosis tools that will provide pathologists grading Follicular Lymphoma samples with quicker, more consistently accurate diagnoses.

31 Jan 2011

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

Allergan, and MAP Pharmaceuticals, today announced a collaboration within the United States for LEVADEX, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adults.

31 Jan 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

Medical Condition News

Health Canada approves Microsulis Medical's Accu2i percutaneous microwave tissue ablation system

Research sheds new light on venous thromboembolism following liver resections

Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

Mayo Clinic opens new center to deliver optimal health care solutions

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Eurogentec, ImaginAb announce collaboration to produce engineered antibody fragments

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

Scientist identifies natural signaling molecule that can prevent Hemophilia A

New research finding shows strong relationship between gut bacteria and fatty liver

Abbott receives US regulatory clearance and Japanese approval for TREK Coronary Dilatation Catheters

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

MRI T2 can determine iron overload in beta-thalassemic patients

Researchers study peripheral blood Tregs as disease marker of gastric cancer

FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator

Cappella initiates multi-center Italian Sideguard open label clinical study

Histamine can be an important molecule to develop new treatments for MS

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

Researchers to develop computer-assisted diagnosis tools for pathologists

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News